[
  {
    "ts": null,
    "headline": "Looking at the Narrative for Centene as Analyst Sentiment Shifts on Profit Outlook",
    "summary": "Centene’s stock has recently seen its consensus analyst price target rise from $36 to $39.76 per share. This marks a moderate upward revision as Wall Street digests the latest developments. The shift reflects growing optimism following strong quarterly results and an improved company outlook, although some lingering caution remains among analysts. Stay tuned to learn how you can keep up with the evolving Centene narrative as expert sentiment continues to shift. Analyst Price Targets don't...",
    "url": "https://finnhub.io/api/news?id=e0b32ed9c061e63583e3aad775ba27a60cc4cecafffbf047975614add4c63b96",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762622504,
      "headline": "Looking at the Narrative for Centene as Analyst Sentiment Shifts on Profit Outlook",
      "id": 137384681,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TFC",
      "source": "Yahoo",
      "summary": "Centene’s stock has recently seen its consensus analyst price target rise from $36 to $39.76 per share. This marks a moderate upward revision as Wall Street digests the latest developments. The shift reflects growing optimism following strong quarterly results and an improved company outlook, although some lingering caution remains among analysts. Stay tuned to learn how you can keep up with the evolving Centene narrative as expert sentiment continues to shift. Analyst Price Targets don't...",
      "url": "https://finnhub.io/api/news?id=e0b32ed9c061e63583e3aad775ba27a60cc4cecafffbf047975614add4c63b96"
    }
  },
  {
    "ts": null,
    "headline": "Looking at the Narrative for Treace Medical Concepts After Analyst Revisions and Growth Concerns",
    "summary": "Treace Medical Concepts has recently seen its consensus analyst price target cut from $8.58 to $6.56, reflecting a notable reduction in perceived fair value. While analyst notes highlight encouraging developments in product expansion and market positioning, they also cite more cautious guidance and growing questions about the sustainability of recent growth. As the story unfolds, stay tuned to learn how to keep up with new updates and shifts in the company's evolving investment...",
    "url": "https://finnhub.io/api/news?id=9b8db55225e7c8663fa653853b5e1253b5fe4461373da0fdd2bdca457d8998c1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762596602,
      "headline": "Looking at the Narrative for Treace Medical Concepts After Analyst Revisions and Growth Concerns",
      "id": 137378530,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TFC",
      "source": "Yahoo",
      "summary": "Treace Medical Concepts has recently seen its consensus analyst price target cut from $8.58 to $6.56, reflecting a notable reduction in perceived fair value. While analyst notes highlight encouraging developments in product expansion and market positioning, they also cite more cautious guidance and growing questions about the sustainability of recent growth. As the story unfolds, stay tuned to learn how to keep up with new updates and shifts in the company's evolving investment...",
      "url": "https://finnhub.io/api/news?id=9b8db55225e7c8663fa653853b5e1253b5fe4461373da0fdd2bdca457d8998c1"
    }
  },
  {
    "ts": null,
    "headline": "How Recent Developments Are Shaping the Boston Scientific Investment Story",
    "summary": "Boston Scientific's stock has seen a modest increase in its consensus analyst price target, rising slightly from $126.14 to $126.48. This minor upward adjustment reflects a balance between recent optimism around the company's earnings momentum, strategic acquisitions, and longer-term growth strategy. At the same time, there are more cautious views regarding current valuation and potential market risks. To discover how investors and analysts can keep up with the evolving story of Boston...",
    "url": "https://finnhub.io/api/news?id=87c07dbc48b1fbe0ae10766b7696a0bc8d942fe115288bdfd7f0caf214f9ad19",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762579214,
      "headline": "How Recent Developments Are Shaping the Boston Scientific Investment Story",
      "id": 137378428,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TFC",
      "source": "Yahoo",
      "summary": "Boston Scientific's stock has seen a modest increase in its consensus analyst price target, rising slightly from $126.14 to $126.48. This minor upward adjustment reflects a balance between recent optimism around the company's earnings momentum, strategic acquisitions, and longer-term growth strategy. At the same time, there are more cautious views regarding current valuation and potential market risks. To discover how investors and analysts can keep up with the evolving story of Boston...",
      "url": "https://finnhub.io/api/news?id=87c07dbc48b1fbe0ae10766b7696a0bc8d942fe115288bdfd7f0caf214f9ad19"
    }
  },
  {
    "ts": null,
    "headline": "How Recent Developments Are Shaping the Hexcel Story for Investors",
    "summary": "Hexcel's stock price target has been revised upward, with the Fair Value Estimate now standing at $74.57, up from $72.86. This change reflects renewed optimism as the company launches a substantial $600 million share buyback and maintains strong free cash flow projections. Stay tuned to discover how you can stay informed on Hexcel's evolving story as market conditions change. Stay updated as the Fair Value for Hexcel shifts by adding it to your watchlist or portfolio. Alternatively, explore...",
    "url": "https://finnhub.io/api/news?id=80d824b3895447f2bcbd51137592248422bf0b7a800e1fc42157ed76c574f65c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762579206,
      "headline": "How Recent Developments Are Shaping the Hexcel Story for Investors",
      "id": 137378532,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TFC",
      "source": "Yahoo",
      "summary": "Hexcel's stock price target has been revised upward, with the Fair Value Estimate now standing at $74.57, up from $72.86. This change reflects renewed optimism as the company launches a substantial $600 million share buyback and maintains strong free cash flow projections. Stay tuned to discover how you can stay informed on Hexcel's evolving story as market conditions change. Stay updated as the Fair Value for Hexcel shifts by adding it to your watchlist or portfolio. Alternatively, explore...",
      "url": "https://finnhub.io/api/news?id=80d824b3895447f2bcbd51137592248422bf0b7a800e1fc42157ed76c574f65c"
    }
  }
]